Global Sustainability Frequently Asked Questions

Climate change is impacting both environmental and human health. As a healthcare company with a global presence and as part of building resilient operations, Viatris works to reduce the effects on and of a changing climate. (See our Global Climate Change Policy).

We have set near-term companywide emission reduction targets in line with the latest climate science. These reduction targets have been validated and approved by the Science Based Targets Initiative (SBTi).

The SBTi classified Viatris’ scope 1 and 2 target ambition and has determined that it is aligned with the Paris Agreement’s goal of limiting global warming to 1.5°C above pre-industrial levels.

Our sites have set various short-term companywide strategies to support Viatris’ overall commitments and goals and are in line with our Global Climate Change Policy. Operations leadership has implemented several initiatives throughout the organization to make progress on global and local targets.

Key actions and strategies for making progress toward our SBTi climate targets include:

• Increasing renewable energy usage
• Implementing energy-efficiency projects
• Using alternative fuels and technologies
• Leveraging infrastructure upgrades and utility replacement projects

Viatris is committed to reducing absolute scope 1 and 2 GHG emissions by 42% and absolute scope 3 GHG emissions by 25%, in each case by 2030 from a 2020 baseline year. Our targets are validated and approved by the Science Based Targets initiative (SBTi), which also classified the target for scope 1 and 2 as aligned with the Paris Agreement’s goal of limiting global warming to 1.5°C above pre-industrial levels. As we work to make further progress on our science-based climate targets and approach our target year of 2030, we will continue to assess the appropriate and science-based next phase company-wide targets towards a net zero ambition.

Our targets and the work to reduce GHG emissions in our own operations and external supply chain aim to reduce impact on and from climate change to further support the health of those we serve and build more resilient operations. Our work to build readiness is based, in part, on our most recent climate scenario analysis. Our updated climate scenario analysis from 2024 reconfirmed that Viatris understands its key risks and has implemented relevant plans to manage risks and opportunities related to the transition toward a low-carbon economy. These existing areas of focus are relevant to building more resilient operations and include protecting and enabling stable access to water and maintaining operations during extreme weather events.

The source of renewable electricity varies by sites because of availability, and we look for local opportunities to adopt these naturally replenishing energy sources. At our Komarom, Hungary, facility, for example, we increased the use of renewable electricity by 35% in 2025 over the previous year. At our site in Sandwich, U.K, we transitioned in 2025 to using 100% renewable energy. Our sites have set various short-term plans to support the company’s global climate change strategy and goals and are in line with our Global Climate Change Policy. Operations leadership has implemented several initiatives throughout the organization to make progress on global and local targets.

For examples of work across the Viatris network, performance data and progress, please see our 2025 Sustainability Report.

In addition to the above-noted climate targets, we also have companywide water and waste goals.

Increasing Reliability and Efficiency Across Our Supply Chain

Our work to uphold resilient operations extends beyond our own operations to external supply chain and the transportation of goods. In 2025, we continued engaging our suppliers of API, finished medicinal product, logistics and other indirect services on their GHG reduction programs - to help make progress on Viatris’ scope 3 reduction target.

Our three main freight transportation modes are road, ocean and air and to further shift to ocean and road freight—which is less GHG intensive than air—we have been adjusting our planning and building more time for transportation into our processes, leveraging strong demand data and forecast planning. We have a rapid response system and have established a standard operating procedure to make ocean freight our standard mode.

In 2025, we extended our Mode of Transportation (MOT) Optimization model to more sites. We decreased use of air over the prior year from 52% to 45%, while increasing our use of sea freight over the same time period, to 55% from 48%. Nearly all of our customers now have a default of sea freight on their profiles, and we have made progress on increasing full truckload shipping to optimize the transportation of products.

Engaging with Our External Suppliers

We actively collaborate with our suppliers to enhance the resiliency of our entire supply chain. As a full member of the Pharmaceutical Supply Chain Initiative (PSCI), we are working together to provide training and supplier engagement at scale to increase awareness across the collective supplier base on sustainable and responsible practices, with a focus on robust EHS and social risk mitigation and GHG reduction. That includes completing PSCI assessments of top suppliers. In 2025, we completed more PSCI audits than we had planned for the year. Where a supplier was found to be high risk from an EHS perspective, a mitigation plan and corrective action plans were developed to reduce the risk.

In addition to disclosure in our annual sustainability report, we also report to the CDP climate and water programs. Our responses are available on CDP’s public responses page and provide additional information.

Water is a valuable natural resource, important to the health of the planet and people everywhere. 

At Viatris, we work to advance responsible water stewardship in our operations and support communities’ access to clean water and sanitation. We work to understand and manage water impacts and wastewater through risk assessments, monitoring and periodic audits of all Viatris operations sites to ensure they comply with local regulatory and company water standards.

In 2025, we completed water risk assessments for our facilities in Jadcherla, India; Johannesburg, South Africa; and Dalian, China. These locations were identified under updated guidance in 2024 of water stress areas by the World Resources Institute (WRI), along with our site in San Antonio, Texas, where we plan to complete a water risk assessment in 2026.

In addition to these assessments, we routinely track and monitor total water discharge volumes by destination at each manufacturing, packaging, large R&D and distribution site within our operational control, as part of our environmental programs. This work helps to drive continuous improvement and ensure compliance with regulations as applicable. At our manufacturing facilities, we monitor and record our water use. Wastewater destinations and the volume discharged are tracked for each site in a central database and reviewed monthly, quarterly, annually or as required.

Our locations around the world are implementing different programs to reduce the use of freshwater and increase water reuse.

In all, eight locations in India apply ZLD technology, eliminating liquid discharge from the facilities.

We are a signatory of the UN Global Compact (UNGC) and the UNGC CEO Water Mandate — a platform for business leaders to address global water challenges in collaboration with the UN, governments, civil society organizations and other stakeholders.

Our teams work to identify opportunities to improve water management within our highly regulated industry. The production requirements of our operations, coupled with local regulations and infrastructure, guide the type of water and wastewater management techniques applied.

We have controls, technologies and containment strategies designed to minimize the amount of potential pharmaceutical ingredients that could enter wastewater. We treat all wastewater streams to help ensure compliance with local regulatory and internal standards. In India, multiple sites apply ZLD technology, which eliminates wastewater discharge. To help ensure our ZLD-equipped plants operate effectively, we conduct independent, third-party assessments and will continue to conduct additional evaluations.

From the water risk assessments, sites will develop water conservation plans that address opportunities and risks, with vertical leaders owning the goals. All operations sites are periodically audited to ensure compliance with local regulatory and internal standards.

More information is presented in Viatris’ 2025 Sustainability Report.

Pharmaceuticals may enter the environment through multiple pathways associated primarily with their intended use, including patient excretion, improper disposal by consumers, and use in agriculture and livestock. Emissions arising directly from pharmaceutical manufacturing operations represent a comparatively small proportion of overall pharmaceutical residues detected in the environment. While the scientific understanding of the relationship between pharmaceuticals in the environment (PiE) and potential impacts on human health and ecosystems continues to evolve, addressing PiE requires a holistic, science‑based approach involving a range of stakeholders across the value chain.

Within this context, and consistent with applicable legal and regulatory requirements, we are committed to responsible manufacturing practices and to minimizing emissions from our own operations through proportionate, risk‑based measures. Our approach to managing potential PiE impacts from manufacturing activities is supported by robust governance and includes:

• Risk and Impact Evaluation
• Risk Reduction and Control Measures
• Multi‑stakeholder Engagement and Policy Dialogue

Manufacturing Effluent Risk Assessments

As part of Viatris’ Global EHS Management System, we have a program and technical requirement dedicated to reducing pharmaceuticals in the environment from manufacturing. We conduct qualitative manufacturing effluent risk assessments to determine the appropriate level of control measures needed for manufacturing to protect the environment from releases of pharmaceutical ingredients.

We are expanding our quantitative manufacturing effluent risk assessments to other product classifications beyond previously completed antibiotic assessments. Viatris has a prioritization scheme to help drive the progression of these assessments from a high- to low-risk basis.

We are active participants in several trade association working groups with a focus on responsible effluent management and appropriate disposal of unused medicine. We also collaborated in the development and launch of the AMR Industry Alliance Antibiotic Manufacturing Standard.

Learn more about our commitments, work and progress in Viatris 2025 Sustainability Report.

Recognizing that environmental and human health are interconnected, from the research and development and manufacturing of products to their delivery to customers, Viatris colleagues and partners work throughout the world to further advance sustainable operations and to minimize environmental impact while upholding a reliable supply of medicines.

Viatris has a holistic approach to and integrated management of environmental, health and safety (EHS). We work systematically and continuously to identify ways to protect the environment and minimize our impact through a comprehensive approach that focuses on managing our water, air emissions, waste and energy.

Viatris’ companywide environmental goals are:

• Viatris Inc. commits to reduce absolute scope 1 and 2 greenhouse gas (GHG) emissions 42% by 2030 from a 2020 base year*. Viatris Inc. also commits to reduce absolute scope 3 GHG emissions covering purchased goods and services, capital goods, fuel and energy related activities, and upstream transportation and distribution 25% within the same timeframe. These near-term targets have been validated and approved by the Science Based Targets initiative (SBTi). 
• Perform water risk assessments for all locations in high or extremely-high water risk areas as identified by the World Resources Institute and identify appropriate water conservation initiatives by 2025.
• Achieve a 50% increase in the number of zero landfill locations by 2030.

2020 as baseline
*The target boundary includes land-related emissions and removals from bioenergy feedstock

Our Global EHS Policies, including the Global Environmental Stewardship Policy, the Global Climate Change Policy, the Global Water Policy and the Global Health and Safety Policy, are based on Viatris’ 13 EHS Principles. The policies and principles apply to all Viatris global operations and every level of the organization. Viatris’ Technical Requirements establish global minimum operating requirements for various environmental and safety activities across all operations. Our global programs, guidelines and technical requirements cover topics including:

• Safety
• Waste management
• Wastewater management
• Incident management
• Chemical management
• Process safety
• Ozone-depleting substances and refrigerant management
• Air emissions
• Pharmaceuticals in the environment
• Energy management
• Water management

Implementing these policies, standards and requirements supports compliance with applicable regulations in the countries and locations where we operate, in addition to filling potential gaps where certain regulations may not exist and where our standards provide superior framework.

The EHS Management System (HSE) is based on a four-step cycle for continuous improvement:

Risk Management

At Viatris, we evaluate EHS risks for our colleagues, products, processes and facilities. Per company policies, the Global EHS Management System and technical requirements, each site must utilize EHS risk assessments using a formal process to analyze EHS risks and maintain continuous improvement plans. We assess risks to our network on an ongoing basis and take measures as appropriate to help ensure we can maintain a safe and stable supply of medicines.

Environmental risk management plans include mitigating climate change risks. As part of our risk mitigation efforts, we evaluate natural hazards and impacts from climate change across our operations. Also, our risk mitigation program covers management of ozone-depleting substances, refrigerants and GHG emissions, improving water management and increasing recycling efforts.

Our Policies

We maintain several policies governing our global environmental practices and commitments for own operations and the external supply chain, including:

• Viatris Environmental Stewardship Policy Summary
• Viatris Climate Change Policy
• Viatris Water Policy
• Viatris Code of Business Conduct and Ethics
• Viatris Supplier Code of Conduct

For a more comprehensive description of Viatris environmental work, commitments, management systems and performance, see Viatris 2025 Sustainability Report.

Viatris applies a best-in-class model for environmental health and safety (EHS) management. Our Global EHS Management System covers all of Viatris’ operations and includes global programs, technical requirements and guidelines.

While all sites are mandated to comply with Viatris’ companywide EHS program and standards, we apply a principled approach according to which each site seeks external certification on top of adherence to Viatris’ standards. We have received ISO certification for Environmental Management at 36% of our sites, and external certifications for Health and Safety Management at 26% of our sites, reflecting the strength of Viatris’ own EHS management system and standards. Sites across our internal network that hold external certifications include:

• ISO 14001: 9 (India), 1 (Greater China), 1 (Middle East), 2 (Europe)
• ISO 50001: 2 (Europe)

Sites across our internal network that hold external certifications for Health and Safety Management include:

• ISO 45001: 8 (India), 1 (Greater China),
• 1 (Middle East), OSHA VPP 1 (U.S.)

Viatris is a founding board member of the AMR Industry Alliance (AMRIA), an active member of its Manufacturing Working Group and is committed to partnering across the industry to collectively advance initiatives addressing AMR. To learn about our work in responsible antibiotic manufacturing please see here.

More details are provided in our 2025 Sustainability Report.

Antimicrobial resistance (AMR) is a significant global health challenge impacting millions of people around the world and with the potential to lead to even greater disruptions to care if not addressed. AMR threatens the effective prevention and treatment of an ever-increasing range of infections caused by bacteria, parasites, viruses and fungi.

Viatris takes a multi-pronged approach to actively engage in addressing AMR, both by providing access through our portfolio of more than 90 antimicrobials and in partnership with others. We are a founding member and active board member of the AMR Industry Alliance (AMRIA), the largest life-sciences coalition, with over 100 biotech, diagnostics, generics and research-based pharmaceutical companies and associations joining forces to provide sustainable solutions to curb AMR globally. We also serve as co-chair of the AMRIA Access and Appropriate Use Working group and are a member of the AMRIA Manufacturing Working Group.

AMRIA aims to contibute to lasting solutions by creating broad industry momentum and facilitating collaboration between public and private sectors. With strategic guidance from Viatris and in collaboration with WHO and other global stakeholders, AMRIA developed and published Principles for Pooled Procurement to provide recommendations for purchasers in LMICs seeking private sector participation in pooled procurement mechanisms for antimicrobial resistance products, including antibiotics and diagnostics. These principles highlight key private sector considerations as LMICs manage the multifaceted challenges of ensuring the availability and reliability of supply across WHO AWaRe categories, including regulatory issues, inadequate demand forecasting, unsustainable procurement practices, and the absence of economic models that account for the full value of products.

As a founding member of Sweden’s PLATINEA (PLATform for Innovation of Existing Antibiotics), Viatris in 2025 continued to support efforts to scale PLATINEA across Europe, including through promotion of a BBC StoryWorks film about the group’s work.

Partnering in the Fight Against Antimicrobial Resistance

Viatris is a founding board member of the AMR Industry Alliance (AMRIA), an active member of its Manufacturing Working Group and is committed to partnering across the industry to collectively advance initiatives addressing AMR.

As part of our commitment, we uphold responsible manufacturing in accordance with AMRIA’s Antibiotic Manufacturing Standard. All applicable Viatris manufacturing locations with antibiotic production have been internally assessed and adhere to the standard, including meeting the PNEC (RQ<1) as calculated by mass balance.

We are continuing our supplier assessment program, to conduct assessments of our top antibiotic suppliers’ management and performance. We completed 19 planned audits in 2025.

Expanding External Antibiotic Manufacturing Standards Certifications

Viatris’ injectables manufacturing facility in Bangalore, India, received a British Standards Institute (BSI) Kitemark Certification under the AMRIA Manufacturing Standard for meeting standards aimed at minimizing the environmental risk of AMR. The certification, announced in 2026, covers vancomycin, clindamycin, and tobramycin for all dosage forms manufactured at the Bangalore site for key markets like the U.S., Australia, and Malaysia.

Five sites in Viatris’ network in Australia, Germany, India and Ireland, have earned the British Standards Institute (BSI) Kitemark Certification under the AMRIA Manufacturing Standard for meeting standards aimed at minimizing the environmental risk of AMR.

The Antibiotic Manufacturing Standard, published by AMRIA and facilitated by BSI, provides clear guidance to manufacturers in the global antibiotic supply chain to ensure that their antibiotics are made responsibly, helping to minimize the risk of AMR in the environment. These certifications provide independent, third-party assurance and demonstrate that antibiotic residue emissions from solid and liquid waste streams are effectively controlled during manufacturing.

In 2025, Viatris announced a research collaboration agreement with Locus Biosciences to develop newly engineered bacteriophage products for ophthalmic bacterial infections – conditions associated with rising rates of AMR.

To learn more about our work, please see Viatris 2025 Sustainability Report.

Viatris’ Board of Directors oversees management’s efforts with respect to sustainability matters through its Governance and Sustainability Committee. The Global Sustainability function operates as a center of excellence within the Corporate Affairs leadership structure. The Head of Global Sustainability drives the strategic and operational development of sustainability matters across the company, together with key partners. The Chief People and Corporate Affairs Officer reports directly to the Chief Administrative and Transformation Officer and, together with the Head of Global Sustainability, communicates quarterly with the Board on sustainability matters, including corporate environmental and social responsibility matters through the Governance and Sustainability Committee.

The Governance and Sustainability Committee reviews progress with the Chief People and Corporate Affairs Officer and Head of Global Sustainability on sustainability matters on an annual basis to confirm the company is tracking its priorities in this area. The Head of Global Sustainability drives the strategic and operational development of sustainability across the company together with key partners.

A multifunctional Advisory Committee comprising of global leaders with a monthly meeting cadence monitors the external landscape, company progress and supports the integration of corporate environmental and social responsibility activities across the organization, including progress on companywide goals and priorities on access, people and the environment.

Progress on strategic focus areas and execution of relevant tasks relies on a broad and engaged network of functional leaders across the company. Additional structured forums are convened on a monthly to quarterly cadence, addressing areas of focus with regard to sustainability for specific key functions, such as the Sustainable Sourcing Council and others, complementing the advisory committee.

Learn more about our continuous work to advance more sustainable operations and responsible practices in Viatris’ 2025 Sustainability Report.

Clinical operations, including clinical trials, are key to advancing access to medicine for patients across the world. Viatris is committed to conducting clinical trials in an ethical way and promoting patient safety and the protection of patient rights throughout a study’s lifecycle.

Our clinical research program and applicable standard operating procedures are global in scope and designed to adhere to international best practice as defined in the Declaration of Helsinki, the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (CH) framework and Good Clinical Practice (GCP).

In 2025, we continued research activities across diverse regions in which patients may experience various healthcare and/or economic challenges and in therapeutic areas that are part of expanding Viatris’ mission to promote access to medicines for research participants and patients around the world. Clinical studies continued in Europe, Africa, Asia-Pacific and North America. We expanded studies in 2025 in areas including Egypt, Lebanon, Jordan, Japan and more. Our research continued in various therapeutic areas including mental health disorders, COPD, chronic and progressive autoimmune disease and women’s health, among others.

We conduct clinical trials in many regions of the world as part of the process to eventually make treatments available to patients globally. To support the further expansion of Viatris’ portfolio and bring more products to more patients with diverse needs, we are increasing the number of trials in new settings. Moving forward, Viatris will continue to work to include patient representatives of the regions where approval is sought, focusing on improving patient access to needed therapies globally.

Global Standards for Responsible Clinical Operations

Whether our clinical trials are performed in house or by a qualified third party, the same global standards apply including adherence to GCP and promoting adherence to applicable policies, procedures and regulatory requirements.

Patient safety and data integrity are at the core of our program. We develop clinical study protocols for each clinical trial that contain criteria and procedures for the conduct of every trial. The procedures for clinical site assessments are developed prior to the selection of investigators. The company maintains procedures that require ongoing evaluation of a clinical site’s conduct of clinical studies from the study’s initiation through the study’s completion. We work with partners to help ensure that clinical investigators are carefully screened prior to being selected to participate in a clinical study and require that clinical investigators conduct careful screening and selection of patients consistent with written study protocols.

Clinical Trials

Clinical trials that include a wide range of patients can yield better, more robust results. As a global healthcare company serving more than 165 countries and territories, Viatris works to include varied patient populations for global studies that will be submitted for approval to health authorities around the world. Viatris works with health authorities to enhance safety and scientific rigor in our clinical trials.

Health authorities across the globe have called for increased pediatric research to support accurate labelling for pediatric populations. Viatris is committed to complying with applicable GCP requirements to ensure pediatric clinical trial requirements are implemented with a focus on patient safety and integrity. In addition:

• Viatris is supporting drug development in multiple regions around the world with applicable development programs that allow for enrollment across a broad range, including both children and adults.
• Further, women of child-bearing potential may also enroll with adequate birth control measures in place.

Required Training

All applicable colleagues and partners involved in clinical operations working on behalf of Viatris are required to be qualified by specific training, including on GCP. Further additional learning and experience are required as applicable to participate in administering clinical trials. Therapeutic area training and study-specific training are provided to applicable team members whether they are Viatris employees, partners or investigational site staff.

Risk Management in Clinical Development

The quality management system provides procedures on assessing potential risks associated with the various aspects of clinical development, such as study design, vendor selection, site selection and patient populations. The application of data analytics supports efficient trial management and oversight.

A more comprehensive description of responsible clinical operations at Viatris is presented in our 2025 Sustainability Report.

We do not conduct animal testing unless it is required by national regulations. We are committed to the “3R” approach (Replacement, Reduction and Refinement) with respect to ethical animal testing. Facilities performing animal testing on our behalf are required to comply with regional scientific procedures for laboratory animal science. These facilities use and/or are approved by the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC). Our Global Operations Audit (GOA) team performs regular audits on entities and facilities involved in animal testing to help ensure compliance. In 2025, GOA audited 13 AAALAC-certified facilities.

We are a global healthcare company whose mission is to empower people worldwide to live healthier at every stage of life. We are purpose-built to make a positive impact for patients and healthcare systems with a dynamic portfolio spanning generics, established brands and innovative medicines that address areas of significant unmet need.

Our global operations and internal and external supply chain are designed to allow us to remain a reliable and flexible partner with a global footprint that adapts to an always changing and increasingly dynamic landscape. Partnerships and collaborations are essential to achieving meaningful and lasting impact; to support reliable access to medicines and consistent quality standards, we work with an array of internal, regional, local and both public and private organizations.

We consistently strive to connect more people with even more products and services to advance access and health. Ultimately, we know we are stronger together, working collaboratively across our company and with industry partners as well as the broader global community, in pursuit of access.

Broad geographic footprint to help enable access: We have our own presence in approximately 70 markets and reach more than 165 countries and territories.

We are convinced that patients and systems around the world are best served by a healthcare company applying a well-rounded and long-term approach, maintaining viability while working to manage inherent risks and opportunities and continuously striving to advance sustainable operations and responsible practices in a focused way.

Access to medicine begins with sustainably delivering high-quality medicines and health solutions at scale to people, regardless of geography or circumstance. Viatris was formed to bridge the traditional divide between generics and brands, combining the best of both, to address healthcare needs more holistically globally. With an extensive portfolio of medicines to meet nearly every health need; a global, diverse and agile supply chain designed to reach more people with health solutions when and where they need them; and the scientific expertise to address some of the world’s most enduring health challenges, access is central to everything we do.

Viatris offers quality treatment options across more than 10 major therapeutic areas covering a wide variety of noncommunicable diseases (NCDs) and infectious diseases. We also enable support services such as diagnostic clinics, educational seminars and digital tools to help patients better manage their health. We offer a broad and diverse range of product options across all our therapeutic areas, with many categories containing several products in a range of dosage forms, formulations and delivery systems that allow physicians to tailor care for people’s needs. Viatris’ Board of Directors oversees management’s efforts to execute on the company’s corporate strategy, including helping to improve access to medicine worldwide. Access is fundamental to our mission. It is not an initiative; it is our business model. Our corporate strategy includes doing our part to increase sustainable access to medicine, as we strive to help build more resilient healthcare systems for people across the world by executing core operations across research and development, manufacturing, supply chain, distribution and market outreach and policy engagement. In addition, community engagement and philanthropic donations complement those core activities.

For more comprehensive description of our work, portfolio and reach, please see our 2025 Sustainability Report.

Public policies are central factors in determining healthcare interventions and patient access. Viatris leverages our global experiences, scientific expertise and operations knowledge to support policymakers in identifying policies that advance access to quality medicines and build systems that sustain medicine availability while minimizing unintended consequences.

Viatris’ Global Policy Issue Briefs outline our positions on a variety of key policy topics. These resources are designed to share our expertise and experience with our global partners and stakeholders, offering a clear view into our understanding of the path ahead for advancing access for patients.

For more information, visit our Public Policy webpage.

At Viatris, we provide an exceptionally broad and diverse portfolio for patients across a range of major therapeutic areas, spanning both noncommunicable and infectious diseases. Our global portfolio includes best-in-class, iconic brand-name products as well as global key brands and generics, including branded and complex generics. Many of the medicines in our portfolio are not protected by patents and are subject to a general trend of price deflation over time.

As we participate in tender programs or public private partnerships around the globe, we evaluate the price of the generics within our portfolio based on an assessment of patients’ need, supply, demand, the cost of manufacturing and the affordability of our products, especially as it relates to the equivalent brand name drug, among other determinants. Other factors considered when pricing our branded portfolio include their value to patients, payers, and health systems.

Working to ensure that patients across all income levels have access to the medicines we offer means we must carefully evaluate the socioeconomic conditions within each market where Viatris does business while simultaneously advancing our ability to consistently provide patients with a reliable supply of the quality products they need. We work to provide holistic solutions for governments, NGOs and health systems globally, as we partner to connect more people to products and services.

Learn more how we work to provide access at scale in our 2025 Sustainability Report.

Describe the core values that shape Viatris’ culture?

Viatris brings together committed and talented individuals who help make our shared work of building access at scale and improving healthcare around the world a reality.

Thriving Together Through Health, Purpose and Growth

Our mission drives our deep commitment to the overall mental and physical health of our colleagues. Viatris’ global wellbeing program, Elevate, encourages colleagues to live life fully via the principles of health, purpose and growth.

Building a Culture of Connection, Mutual Respect and Inclusivity

At Viatris, our workplace culture is one of our greatest strengths. We foster a culture of connection, mutual respect, and inclusivity and we encourage colleagues to learn, grow and achieve together. The insights from our employee engagement and listening strategies guide our efforts as we strive to create a work environment where people can feel appreciated and make an impact on the world. We seek perspective in a variety of ways and encourage healthy interactions for all. With a significant global footprint, our colleagues represent a variety of geographies, cultures and circumstances, and we support each of them doing their best work.

Learning and Development for High Performance

We believe continuous learning is a mindset that fuels our mission. We foster a culture of learning and focused development, where every colleague is encouraged and equipped to grow professionally and purposefully. Our philosophy is grounded in the belief that when colleagues are empowered to grow and share learnings, we can all strengthen collaboration and accelerate innovation. Through our Viatris Learning and Development (L&D) programs, colleagues are encouraged to:

• Continuously learn. Stay curious and build the knowledge, skills and agility to succeed in a rapidly evolving world of science and healthcare.
• Grow intentionally. Pursue development that inspires them to achieve their goals.
• Learn collaboratively. Share knowledge, teach and mentor others, and contribute to a culture of high performance.

Learn more about our work in Viatris’ 2025 Sustainability Report and on our career website.

Protecting patients and consumer health by ensuring the quality and safety of our products is at the heart of how we operate across our network. Every step of our development, manufacturing and monitoring processes – from developing products to sourcing of raw materials to producing and distributing finished dosage forms – is grounded in this commitment.

All of Viatris’ operations, manufacturing sites and our contract manufacturing organizations (CMOs) globally are subject to robust quality infrastructure and strategy. This infrastructure is composed of the extensive experience and expertise of our personnel and our comprehensive Global Quality policies, procedures and guidelines. These establish uniform requirements for fundamental processes and controls within our Global Quality Management System (QMS), as well as Global Quality IT systems, which are implemented and designed to establish industry best practices, consistency and global quality assurance throughout our network.

We continuously evolve our quality organization for alignment with our business operations and to support compliance with applicable standards. Existing global quality resources are embedded within operational verticals to align closely with business units and drive consistency across sites.

We work to incorporate relevant external quality guidelines, from across the world, into our Global Quality Policies and Management Systems, including: Eudralex, Falsified Medicines Directive, ICH Quality Guidelines, WHO GMP, U.S. Food and Drug Administration Safety and Innovation Act, Code of Federal Regulations and the EU Excipient Risk Assessment for ascertaining the GMPs and regulatory expectations for the excipients of medicinal products for human use. We have developed and maintain a Regulatory Intelligence, Quality Action System and Knowledge Management Dissemination Program to inform, evaluate and implement regulatory updates, industry trends and internal knowledge across the Viatris network.

In addition to continuously monitoring and evolving our approach to quality, colleagues around the world are provided training on quality culture to ensure personnel have a clear understanding of our commitment to quality. In 2026, we are continuing to enhance our Cultural Excellence program to engage employees and reinforce the importance of quality compliance and the impact of noncompliance.

Specific training sessions, town hall meetings and messaging are part of the culture program enhancement, focusing on building individual awareness about quality, reinforcing a culture of real-time feedback on quality issues and robust oversight and accountability for compliance.

Quality Risk Assessment

Quality Risk Management is central to our approach to quality. We apply the principles outlined in the International Conference of Harmonization (ICH) Q9 Quality Risk Management as well as those in the ICH Q10 Pharmaceutical Quality System.

A High-Quality Supply Chain

Viatris relies on our partners to deliver high-quality medicines. A highly experienced Viatris cross-departmental committee, including Sourcing and Quality, undertakes a rigorous review of suppliers and third parties prior to their selection for the supply of active pharmaceutical ingredients and drug products. 

Working with Health Authorities

We constantly review our products, processes and facilities throughout our network and work closely with external health authorities to ensure transparency regarding emerging information, including shortages, the development of new scientific and testing criteria and evolving regulatory and manufacturing expectations everywhere we operate. We continuously learn from these interactions as scientific, technological and regulatory expectations continue to evolve. In 2025, more than 95 health authority inspections were conducted across our facilities.

External Engagement on Quality

Viatris actively engages and collaborates with external stakeholders to advance quality management in the pharmaceutical sector. We are members of and have representatives on key recognized industrywide partnerships and groups such as the International Society for Pharmaceutical Engineering (ISPE) and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). We are active participants in ISPE’s Core Team on Advancing Pharmaceutical Quality (APQ) program, an industry-led quality management maturity assessment and benchmarking program.

To learn more about our work and procedures, see Viatris 2025 Sustainability Report.

Effective quality and product safety management systems are designed to detect and manage potential risks. These programs may result in Health Authority Notifications (such as Field Alert Reports) and/or product recalls as part of their design. Health Authority Notifications can be used to quickly identify potential quality defects in distributed drug products that may present a possible risk. Recalls are largely initiated voluntarily as a precautionary measure in cases of possible risk to the quality and safety of the product and/or the patient.

However, a recall decision is not always driven by quality concerns in the medicine itself and may be conducted for other reasons such as changes to artwork or labeling. There is currently no globally harmonized international standard on what constitutes a recall. Viatris has established standard best practices through the implementation of a global standard operating procedure detailing the notification and assessment of critical quality events to determine whether notification to the national health authorities and/or a recall will be conducted. Such decisions are made in alignment across Quality, Pharmacovigilance, Legal Regulatory and Communications teams including the oversight of the Head of Global Quality Operations. Each site must develop and maintain a written procedure to govern the recall of products based upon local health authority regulatory requirements in the territories in which their respective products are provided. A product recall serves to safeguard the health of patients, demonstrating our responsibility and the efficacy of the Quality Management System (QMS).

It is relevant to point out that as the vast majority of recalls are voluntary and not mandated by health authorities, the level of conservatism demonstrated by a company can influence its total number of recalls. This number is also heavily impacted by the type and number of products within a company’s portfolio, along with other factors.

Viatris’ principal approach to reduce GHG emissions across both our own operations and the external supply chain is through companywide, science-based GHG emissions reduction targets, across scope 1, 2 and 3. In parallel, we have piloted targeted product-level carbon footprint assessments, in response to regulatory requirements and public procurement processes. These assessments have been conducted in line with recognized carbon accounting principles, with system boundaries and emissions scopes adapted to applicable regulatory or procurement frameworks and available data.

With an access-driven, broad, and diverse portfolio, companies like Viatris face unique structural challenges that significantly impact the feasibility and utility of this product-based approach. Viatris believes that environmental criteria should be measurable and unambiguous, so assessments are clear and comparable; directly targeted to true environmental impact, not proxies or vague commitments; and designed to advance sustainable practices while protecting global, diverse supply chains and preserving access to medicine.

To do this, Viatris advocates for:

• broader, company-level criteria, such as GHG emissions targets, to better reflect strategic environmental commitments and measurable actions; and
• evaluating suppliers against harmonized, science-based criteria at the company level to enable procurement systems to incentivize meaningful, system-wide improvements while maintaining supply chain resilience and ensuring equitable access to medicines

More details are provided in our 2025 Sustainability Report.